STP938: At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.
Study summary
The goal of this clinical trial is to learn if the drug STP938 works to treat adults with high risk essential thrombocythaemia (ET) who are resistant to, or intolerant of, hydroxycarbamide (also known as hydroxyurea) therapy. The trial will also learn about the safety of STP938. The main questions the trial aims to answer are:
* Does STP938 control platelet counts
* Does STP938 control platelet counts without inducing unwanted side effects
Participants will:
* Take STP938 every day for up to 12 months.
* Visit the clinic once every week for the first month, then every 2 weeks for checkups and tests.
* Complete a questionnaire about symptoms once a month.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria:
* Adults aged 18 years or older
* A confirmed diagnosis of ET according to World Health Organisation (WHO) or British Society for Haematology (BSH) criteria.
* Meeting criteria for high risk ET.
* Raised platelet count (\>600 x109/L) requiring cytoreductive therapy.
* Neutrophil count \>1.0 x109/L.
* Either intolerant of or resistant to hydroxycarbamide having met any one of the criteria at any point in their disease whilst receiving hydroxycarbamide.
* Adequate hepatic function.
* Adequate blood coagulation parameters.
* Eastern Cooperative Oncology Group (ECOG) status of 0-2.
Key Exclusion Criteria:
* Subjects currently or recently receiving cytoreductive therapy for the treatment of essential thrombocythaemia (wash out periods apply).
* Subjects who have received any investigational agents for the treatment of essential thrombocythaemia within 4 weeks before enrolment or less than 5 half-lives since completion of prior therapy, whichever is shorter.
* Proven or suspected transformation to polycythaemia vera, myelofibrosis, myelodysplasia, acute myeloid leukaemia or another myeloid neoplasm.
* Known malabsorption syndrome or other condition that may impair absorption of study medication (e.g. gastrectomy).
* Previous splenectomy.
* Any uncontrolled intercurrent illness.
* Immunocompromised subjects with increased risk of opportunistic infections.
* Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.
* Pregnant females, breastfeeding females, and women of child bearing age or males not willing to comply with contraceptive requirements.
* Known hypersensitivity to any of the excipients used in the formulation of the study drug.
* Corrected QT interval \>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).
Primary outcome measure(s)
Clinical Efficacy — Through study completion, an average of 12 months Complete and partial response rates per European LeukemiaNet criteria
Safety and Tolerability — Through study completion, an average of 12 months Toxicity profile based on National Cancer Institute Common Terminology Criteria for Adverse Events
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.